The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Buhl, Roland ^a   Kuna, Piotr ^b   Peters, Matthew J ^c   Andersson, Tomas L G ^d   Naya, Ian P ^d   Peterson, Stefan ^d   Rabe, Klaus F ^e  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c ANZAC Research Institute   (Australia)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF KIEL   (Germany)

Author keywords

Asthma; Asthma in primary care

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; EVOHALER; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; SYMBICORT SMART; TERBUTALINE; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; BUDESONIDE; ETHANOLAMINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXAMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HUMANS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84867116634     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-59     Document Type: Article

References (33)

1. Eisner MD, Lieu TA, Chi F, Capra AM, Mendoza GR, Selby JV, Blanc PD. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001, 17:233-240. 10.1183/09031936.01.17202330, 11334125.
2. Lanes SF, Garcia Rodriguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002, 57:683-686. 10.1136/thorax.57.8.683, 1746414, 12149527.
3. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992, 326:501-506. 10.1056/NEJM199202203260801, 1346340.
4. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002, 57:880-884. 10.1136/thorax.57.10.880, 1746208, 12324675.
5. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997, 337:1405-1411. 10.1056/NEJM199711133372001, 9358137.
6. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 2001, 107:783-789. 10.1067/mai.2001.114709, 11344343.
7. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, Lofdahl CG, Pauwels RA, Ullman A. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999, 160:594-599.
8. Asthma GI. Global strategy for asthma management and prevention - updated 2008 2008, , , (accessed 1 Dec 2009)http://www.ginaasthma.com.
9. Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, Carlsheimer A. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007, 101:2437-2446. 10.1016/j.rmed.2007.07.014, 17905575.
10. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, Buhl R. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007, 61:725-736. 10.1111/j.1742-1241.2007.01338.x, 1920547, 17362472.
11. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171:129-136.
12. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006, 368:744-753. 10.1016/S0140-6736(06)69284-2, 16935685.
13. Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, Lier PA, Jorup C. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006, 129:246-256. 10.1378/chest.129.2.246, 16478838.
14. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, Boulet LP, Naya IP, Hultquist C. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004, 20:1403-1418. 10.1185/030079904X2051, 15383189.
15. Vogelmeier C, D'Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, Naya I, Price D. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. Eur Respir J 2005, 26:819-828. 10.1183/09031936.05.00028305, 16264042.
16. Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, Jenkins C, Humbert M, Buhl R, Harrison TW, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010, 125:600-608-608 e601-608 e606.
17. Chapman KR, Barnes NC, Greening AP, Jones PW, Pedersen S. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax 2010, 65:747-752. 10.1136/thx.2009.128504, 2975956, 20581409.
18. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007, 29:587-595. 10.1183/09031936.00080306, 17329493.
19. Aalbers R, Backer V, Kava TT, Omenaas ER, Sandstrom T, Jorup C, Welte T. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004, 20:225-240. 10.1185/030079903125002928, 15006018.
20. FitzGerald JM, Gibson PG. Asthma exacerbations 4. Prevention Thorax 2006, 61:992-999.
21. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004, 363:271-275. 10.1016/S0140-6736(03)15384-6, 14751699.
22. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest 2000, 117:440-446. 10.1378/chest.117.2.440, 10669688.
23. Oborne J, Hubbard RB, Tattersfield AE. Can acute exacerbations of asthma be prevented with a four-fold increase in inhaled corticosteroid dose?. Am J Respir Crit Care Med 2009, 179:A2794.
24. Duong M, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M, Howie K, Killian K, O'Byrne PM. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol 2007, 119:322-327. 10.1016/j.jaci.2006.10.018, 17141859.
25. Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am J Respir Crit Care Med 2001, 163:32-36.
26. Paggiaro PL, Dente FL, Morelli MC, Bancalari L, Di Franco A, Giannini D, Vagaggini B, Bacci E, Fabbri LM, Giuntini C. Postallergen inhaled budesonide reduces late asthmatic response and inhibits the associated increase of airway responsiveness to methacholine in asthmatics. Am J Respir Crit Care Med 1994, 149:1447-1451.
27. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest 2006, 130:1301-1311. 10.1378/chest.130.5.1301, 17099004.
28. Sears MR, Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 2009, 103:1960-1968. 10.1016/j.rmed.2009.08.007, 19815402.
29. Anderson GP. Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation. Am J Respir Crit Care Med 2000, 161:S188-196.
30. van Veen A, Weller FR, Wierenga EA, Jansen HM, Jonkers RE. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther 2003, 16:153-161. 10.1016/S1094-5539(03)00003-8, 12749831.
31. Molimard M, Naline E, Zhang Y, Le Gros V, Begaud B, Advenier C. Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J 1998, 11:583-588.
32. Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, Thabane L, Cheng J, Schunemann HJ, Sears MR, Guyatt G. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 2008, 178:1009-1016. 10.1164/rccm.200804-494OC, 18776152.
33. Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma, A systematic review. Pulm Pharmacol Ther 2009, 22:9-19. 10.1016/j.pupt.2008.10.008, 19026757.